Bp5250 inhibits vascular endothelial growth factor-induced angiogenesis and HIF-1α expression on endothelial cells
- 338 Downloads
Angiogenesis plays a critical role in many physiological and pathological phenomena. A number of anti-angiogenesis drugs have been used in the clinical treatment of diseases such as malignant tumors and macular degeneration. Vascular endothelial growth factor (VEGF), the major pro-angiogenesis factor, is known to stimulate various steps of endothelial angiogenic activity, such as proliferation, migration, and differentiation into vessel-like tubes. In this study, we tested the effects of bp5250 on the angiogenesis of human umbilical endothelial cells (HUVECs). Bp5250 suppressed VEGF-induced endothelial cell proliferation by triggering apoptosis, and reduced endothelial cell migration toward VEGF. Bp5250 also decreased VEGF-stimulated tube formation and rat aortic ring sprouting on Matrigel in a concentration-dependent manner. In the VEGF-activated signaling pathways, bp5250 decreased the phosphorylation of ERK, p38, PI3K-AKT, Src, and FAK and also reduced the activation of the cytoskeleton-associated Rho family, all in a concentration-dependent manner. Bp5250 also attenuated the hypoxia-inducible factor-1α (HIF-1α) and VEGF-stimulated mRNA expression of HUVECs under the hypoxic condition. In vivo, angiogenesis was restrained by a daily intraperitoneal administration of bp5250 in a dose-dependent manner (1–3 mg/kg/d) in the Matrigel plug implantation assay. These results indicate that bp5250 is a potential candidate for developing anti-angiogenic agents.
KeywordsAngiogenesis Vascular endothelial growth factor Endothelial cell Hypoxia-inducible factor-1α
This work was supported by grants from the National Science Council (NSC97-2323-B-002-008, NSC98-2323-B-002-009, NSC99-2323-B-002-004 and NSC99-2320-B-039-010-MY3) of Taiwan.
Conflict of interest
The authors state that there is no conflict of interest.
- Bondavalli F, Bruno O, Ranise A, Schenone P, Losasso C, Stella L et al (1990) 3,5-Diphenyl-1H-pyrazole derivatives. VI—Esters and 2-dialkylaminoethyl ethers of 1(2-hydroxy-2-phenylethyl)-3,5-diphenyl-1H-pyrazole and N, N-disubstituted 1-(2-amino-2-phenylethyl)-3,5-diphenyl-1H-pyrazoles with depressant and platelet antiaggregating activities. Farmaco 45(5):511–526PubMedGoogle Scholar
- Genin MJ, Biles C, Keiser BJ, Poppe SM, Swaney SM, Tarpley WG et al (2000) Novel 1,5-diphenylpyrazole nonnucleoside HIV-1 reverse transcriptase inhibitors with enhanced activity versus the delavirdine-resistant P236L mutant: lead identification and SAR of 3- and 4-substituted derivatives. J Med Chem 43(5):1034–1040PubMedCrossRefGoogle Scholar
- Liu YN, Pan SL, Peng CY, Guh JH, Huang DM, Chang YL et al (2006) YC-1 [3-(5'-hydroxymethyl-2'-furyl)-1-benzyl indazole] inhibits neointima formation in balloon-injured rat carotid through suppression of expressions and activities of matrix metalloproteinases 2 and 9. J Pharmacol Exp Ther 316(1):35–41PubMedCrossRefGoogle Scholar
- Mirshahi P, Toprak SK, Faussat AM, Dubrulle S, Marie JP, Soria C et al (2006) Malignant hematopoietic cells induce an increased expression of VEGFR-1 and VEGFR-3 on bone marrow endothelial cells via AKT and mTOR signalling pathways. Biochem Biophys Res Commun 349(3):1003–1010PubMedCrossRefGoogle Scholar
- Nicosia RF, Ottinetti A (1990) Modulation of microvascular growth and morphogenesis by reconstituted basement membrane gel in three-dimensional cultures of rat aorta: a comparative study of angiogenesis in matrigel, collagen, fibrin, and plasma clot. Vitro Cell Dev Biol 26(2):119–128CrossRefGoogle Scholar